BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
22.47
-1.25 (-5.27%)
Nov 18, 2024, 3:23 PM EST - Market open
BridgeBio Pharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2017 |
| Revenue | 217.77 | 9.3 | 77.65 | 69.72 | 8.25 | 40.56 | Upgrade
|
| Revenue Growth (YoY) | 2209.77% | -88.02% | 11.38% | 745.14% | -79.66% | - | Upgrade
|
| Cost of Revenue | 2.39 | 2.45 | 3.43 | 3.11 | - | 2.5 | Upgrade
|
| Gross Profit | 215.37 | 6.86 | 74.21 | 66.6 | 8.25 | 38.06 | Upgrade
|
| Selling, General & Admin | 225.23 | 150.59 | 143.19 | 188.91 | 145.68 | 94.35 | Upgrade
|
| Research & Development | 506.34 | 455.71 | 399.46 | 451.02 | 337.05 | 209.95 | Upgrade
|
| Operating Expenses | 731.57 | 606.3 | 542.65 | 639.93 | 482.73 | 304.3 | Upgrade
|
| Operating Income | -516.2 | -599.44 | -468.44 | -573.33 | -474.48 | -266.24 | Upgrade
|
| Interest Expense | -89.74 | -81.29 | -80.44 | -46.78 | -36.66 | -8.77 | Upgrade
|
| Interest & Investment Income | 18.14 | 18.04 | 7.54 | 1.13 | 4.02 | 8.92 | Upgrade
|
| Earnings From Equity Investments | -14.49 | - | - | - | - | -20.87 | Upgrade
|
| Other Non Operating Income (Expenses) | 3.03 | 0.3 | 102.43 | 3.7 | 1.63 | -1.63 | Upgrade
|
| EBT Excluding Unusual Items | -599.25 | -662.4 | -438.9 | -615.28 | -505.49 | -288.59 | Upgrade
|
| Merger & Restructuring Charges | -11.67 | -7.93 | -43.77 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 29.4 | 18.31 | -8.22 | 29.91 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 178.32 | -1.24 | -6.26 | - | - | - | Upgrade
|
| Asset Writedown | - | - | - | -3.3 | - | - | Upgrade
|
| Other Unusual Items | -43.09 | - | 12.5 | 2.21 | - | - | Upgrade
|
| Pretax Income | -446.29 | -653.25 | -484.65 | -586.45 | -505.49 | -288.59 | Upgrade
|
| Earnings From Continuing Operations | -446.29 | -653.25 | -484.65 | -586.45 | -505.49 | -288.59 | Upgrade
|
| Minority Interest in Earnings | 7.43 | 10.05 | 3.47 | 23.92 | 56.76 | 28 | Upgrade
|
| Net Income | -438.86 | -643.2 | -481.18 | -562.54 | -448.72 | -260.59 | Upgrade
|
| Net Income to Common | -438.86 | -643.2 | -481.18 | -562.54 | -448.72 | -260.59 | Upgrade
|
| Shares Outstanding (Basic) | 182 | 163 | 147 | 144 | 118 | 105 | Upgrade
|
| Shares Outstanding (Diluted) | 182 | 163 | 147 | 144 | 118 | 105 | Upgrade
|
| Shares Change (YoY) | 16.50% | 10.39% | 2.16% | 22.34% | 12.27% | 70.15% | Upgrade
|
| EPS (Basic) | -2.41 | -3.95 | -3.26 | -3.90 | -3.80 | -2.48 | Upgrade
|
| EPS (Diluted) | -2.41 | -3.95 | -3.26 | -3.90 | -3.80 | -2.48 | Upgrade
|
| Free Cash Flow | -451.54 | -529.03 | -424.32 | -511.18 | -407.23 | -256.23 | Upgrade
|
| Free Cash Flow Per Share | -2.48 | -3.25 | -2.88 | -3.54 | -3.45 | -2.44 | Upgrade
|
| Gross Margin | 98.90% | 73.71% | 95.58% | 95.53% | 100.00% | 93.84% | Upgrade
|
| Operating Margin | -237.04% | -6443.56% | -603.28% | -822.38% | -5751.99% | -656.41% | Upgrade
|
| Profit Margin | -201.53% | -6913.92% | -619.70% | -806.90% | -5439.74% | -642.47% | Upgrade
|
| Free Cash Flow Margin | -207.35% | -5686.62% | -546.46% | -733.23% | -4936.74% | -631.72% | Upgrade
|
| EBITDA | -509.9 | -592.95 | -461.67 | -567.49 | -473.03 | -265.38 | Upgrade
|
| D&A For EBITDA | 6.29 | 6.49 | 6.77 | 5.84 | 1.46 | 0.86 | Upgrade
|
| EBIT | -516.2 | -599.44 | -468.44 | -573.33 | -474.48 | -266.24 | Upgrade
|
| Revenue as Reported | - | - | - | - | 8.25 | 40.56 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.